PPARG and neoplasm: In 27 pre-treatment tumor samples from patients receiving ibrutinib plus paclitaxel, subsequent assessments of CR, PR, or SD were significantly associated with higher baseline B- cell signature score (p = 2.9 × 10−4; average score in non-PD: 0.53; average score in PD: 0.19) and lower baseline peroxisome proliferator-activated receptor γ/retinoid X receptor α (PPARG/RXR) signature score (p = 2.1 × 10−6; average score in non-PD: 0.47; average score in PD: 0.88) compared to patients (Figure S1A).